Logo - springer
Slogan - springer

Medicine - Oncology & Hematology | Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer

Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer

Ignatiadis, Michail, Sotiriou, Christos, Pantel, Klaus (Eds.)

2012, XIV, 254 p.

Available Formats:
eBook
Information

Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.

You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.

After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.

 
$169.00

(net) price for USA

ISBN 978-3-642-28160-0

digitally watermarked, no DRM

Included Format: PDF and EPUB

download immediately after purchase


learn more about Springer eBooks

add to marked items

Hardcover
Information

Hardcover version

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
$219.00

(net) price for USA

ISBN 978-3-642-28159-4

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days


add to marked items

Softcover
Information

Softcover (also known as softback) version.

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
$219.00

(net) price for USA

ISBN 978-3-642-44587-3

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days


add to marked items

  • Provides up-to-date information on topical issues concerning minimal residual disease in breast cancer patients
  • Appraises the technologies available for detection and characterization of circulating and disseminated tumor cells (CTCs/DTCs)
  • Discusses the relevance of CTCs and DTCs in breast cancer clinical research and practice, and the role of other blood-based biomarkers

Most deaths from carcinomas are caused by the hematogenous dissemination of cancer cells to distant organs and the eventual development of metastases. When found in the bone marrow or peripheral blood of carcinoma patients, occult cancer cells are referred to as disseminated tumor cells (DTCs) or circulating tumor cells (CTCs). CTCs and DTCs are considered surrogates of minimal residual disease, i.e., the presence of malignant cells in distant organs that are undetectable by conventional imaging and laboratory tests used for tumor staging after curative surgery of the primary tumor.

 

In this book, leading investigators in the field provide up-to-date information on a series of important questions, including:

 

-  How can the study of minimal residual disease and CTCs help us to better understand breast cancer metastasis?

-  What technologies are available for the detection and characterization of CTCs and DTCs, and what are their relative merits?

-  How are DTCs and CTCs relevant to clinical research and practice?

- What is the role of other blood-based biomarkers such as circulating endothelial cells and circulating nucleic acids?

-  What are the challenges in drug and biomarker co-development and the use of CTCs for companion diagnostic development?

 

This book will be of interest and assistance to all who are engaged in the modern management of breast cancer.

Content Level » Professional/practitioner

Keywords » Breast cancer - Circulating nucleic acids - Circulating tumor cells - Micrometastasis - Minimal residual disease

Related subjects » Cancer Research - Gynecology - Oncology & Hematology - Pathology

Table of contents / Preface / Sample pages 

Popular Content within this publication 

 

Articles

Read this Book on Springerlink

Services for this book

New Book Alert

Get alerted on new Springer publications in the subject area of Oncology.